

Evaluating the safety and efficacy of a new chronic plaque psoriasis treatment

PURPOSE OF THIS STUDY:

The primary objective of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged ≥ 6 through < 18 years with chronic plaque psoriasis.

WHO CAN PARTICIPATE?

- Be ≥ 6 To < 18 years of age, have been diagnosed with and have had psoriasis for at least 1 year prior to screening
- Be assessed by your study doctor to meet the minimum requirement for screening and baseline visits

WHAT IS INVOLVED?

- Each subject's trial participation will be up to week 52. A long-term extension (LTE) of the study will be initiated at week 52 and will continue until approval for guselkumab in pediatric plaque psoriasis is obtained or the development of the guselkumab pediatric plaque psoriasis indication is discontinued.
- Physical Exams, blood tests, and questionnaires are some of the tests involved if you choose to participate in the study.

CONTACT INFORMATION:

Jaspal Mor, Study Coordinator
Phone: 604.875.5296
Email: jaspal.mor@ubc.ca

STUDY TIME/DURATION

Ongoing

STUDY LOCATION

Clinical Trials Unit at the Skin Care Centre at VGH

PRINCIPAL INVESTIGATOR

Dr. Vincent Ho

Department of Dermatology and Skin Science

Research Investigator with VCH Research Institute

To learn more about this study, visit vchri.ca/participate



Health research changes lives.

Be part of the discovery.
vchri.ca/participate

Vancouver
CoastalHealth
Research Institute